Clinical Trial

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will also look at how the drug moves through the body, is absorbed, distributed, metabolized and eliminated.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-15; most recent amendment 2026-01-13.
Status change: Recruiting → Completed 2026-01-13
Trial Details
NCT Number NCT07186946
Lead Sponsor Thryv Therapeutics, Inc.
Conditions Heart Failure
Enrollment 16 participants
Start Date 2025-09-15
Primary Completion 2025-10-20 (estimated)
Study Completion 2025-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-14